Bend Bioscience Brand Unites CoreRx and Societal CDMO
In a significant development, CoreRx, Societal CDMO, and Bend Bioscience have come together, merging under the Bend Bioscience brand. This partnership combines the strengths and legacies of three respected organizations into a single, cohesive entity dedicated to providing a comprehensive range of contract development and manufacturing organization (CDMO) services.
Strength Through Unification
The choice of the Bend Bioscience name reflects the company’s commitment to innovation and exceptional customer service—an esteemed reputation cultivated over many years. This merger pays tribute to the rich histories of CoreRx and Societal CDMO, with their expertise forming the foundation of the newly established company.
CoreRx’s Innovative Solutions
CoreRx has positioned itself as a leader in formulation development, renowned for crafting customized solutions to address complex challenges in the pharmaceutical sector. Its profound knowledge of innovative drug delivery systems and intricate formulations will be instrumental in the expanded services provided by Bend Bioscience.
Societal CDMO’s Manufacturing Expertise
Conversely, Societal CDMO contributes substantial experience in scalable manufacturing and commercial production. With a strong focus on maintaining excellence and reliability, their operations in cGMP manufacturing, packaging, and efficient supply chain management will bolster the scientific and technical capabilities of the newly merged organization.
The Vision for Bend Bioscience
Owen Murray, CEO of Bend Bioscience, remarked, "Selecting Bend Bioscience as our unified brand showcases the scientific excellence and innovative spirit that all three companies embody. This merger goes beyond merely sharing resources; it’s about capitalizing on the complementary strengths of CoreRx's advanced formulation capabilities, Societal CDMO's manufacturing expertise, and our innovative research at Bend Bioscience. Together, we aim to deliver unparalleled value and service to our clients and their patients."
Ready to Meet Future Challenges
By consolidating their efforts under the Bend Bioscience name, the new organization is strategically positioned to improve operational efficiencies and leverage their combined expertise. This will empower them to offer high-quality services aimed at accelerating the delivery of life-saving therapies to the market.
About Bend Bioscience
Bend Bioscience is a prominent CDMO formed through the merger of CoreRx, Societal CDMO, and Bend Bioscience itself. The organization specializes in providing innovative solutions for every phase of drug development and manufacturing. With a strong emphasis on quality, science, and exceptional service, Bend Bioscience features advanced facilities in various locations, serving clients globally with a comprehensive range of capabilities. Their mission is to collaborate with clients to transform complex molecules into effective medicines.
For additional information or media inquiries, please contact:
Media Contact Information
Melissa Sullivan
Director of Marketing + Communications
Bend Bioscience
Email: [email protected]
Frequently Asked Questions
What is the significance of the Bend Bioscience merger?
The merger integrates CoreRx and Societal CDMO under the Bend Bioscience brand, strengthening the CDMO service offerings.
How does this merger benefit clients?
This unification enhances capabilities, providing a more comprehensive pathway for drug development and manufacturing.
Who is leading Bend Bioscience post-merger?
Owen Murray serves as the CEO of Bend Bioscience, focusing on innovation and operational excellence.
What areas of expertise does Bend Bioscience cover?
Bend Bioscience specializes in formulation development, scalable manufacturing, and supply chain management.
Where are the facilities of Bend Bioscience located?
Bend Bioscience operates state-of-the-art facilities across multiple locations, improving global service delivery.
